Neonatal Abstinence Syndrome Due to Maternal Kratom Use
- PMID: 30404789
- DOI: 10.1542/peds.2018-1839
Neonatal Abstinence Syndrome Due to Maternal Kratom Use
Abstract
Neonatal abstinence syndrome (NAS) is increasing in incidence and most commonly associated with maternal opioid use during pregnancy. Nonopioid alternatives to treat opioid dependence are highly sought after in the country's current opioid epidemic. Whether Kratom, a legal, widely available herbal supplement, should be classified as an opioid is contentious. Although the US Food and Drug Administration has recently addressed this controversy, Kratom continues to be marketed as a nonopioid remedy for opioid withdrawal. Its use is increasing in the United States. We describe an infant with NAS born to a mother with daily Kratom tea ingestion to self-treat opioid dependence. Pediatricians and parents should be aware of the risk of NAS due to Kratom use during pregnancy.
Copyright © 2018 by the American Academy of Pediatrics.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Similar articles
-
[Neonatal abstinence syndrome due to kratom].Ned Tijdschr Geneeskd. 2023 Sep 28;167:D7541. Ned Tijdschr Geneeskd. 2023. PMID: 37823888 Dutch.
-
Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to 'kratom'.J Neonatal Perinatal Med. 2019;12(1):109-112. doi: 10.3233/NPM-1863. J Neonatal Perinatal Med. 2019. PMID: 30149482 Free PMC article.
-
Novel case of maternal and neonatal kratom dependence and withdrawal.Can Fam Physician. 2018 Feb;64(2):121-122. Can Fam Physician. 2018. PMID: 29449242 Free PMC article. No abstract available.
-
Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review.J Perinatol. 2021 Jun;41(6):1236-1243. doi: 10.1038/s41372-021-00952-8. Epub 2021 Feb 15. J Perinatol. 2021. PMID: 33589723 Free PMC article. Review.
-
Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome.Neonatal Netw. 2016;35(5):277-86. doi: 10.1891/0730-0832.35.5.277. Neonatal Netw. 2016. PMID: 27636691 Review.
Cited by
-
Endogenous Opioid Activity as the Mechanism of Action for Mitragyna speciosa (Kratom): The Current State of the Evidence.Adv Neurobiol. 2024;35:287-313. doi: 10.1007/978-3-031-45493-6_15. Adv Neurobiol. 2024. PMID: 38874729 Review.
-
Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review.Curr Addict Rep. 2023;10(2):317-334. doi: 10.1007/s40429-023-00478-3. Epub 2023 May 12. Curr Addict Rep. 2023. PMID: 37266188 Free PMC article. Review.
-
Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review.Subst Abuse. 2022 May 20;16:11782218221095873. doi: 10.1177/11782218221095873. eCollection 2022. Subst Abuse. 2022. PMID: 35645563 Free PMC article. Review.
-
Kratom Use Among U.S. Adolescents: Analyses of the 2019 National Survey on Drug Use and Health.J Adolesc Health. 2022 Apr;70(4):677-681. doi: 10.1016/j.jadohealth.2021.10.009. Epub 2021 Nov 23. J Adolesc Health. 2022. PMID: 34836801 Free PMC article.
-
The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom (Mitragyna speciosa Korth.): A Comprehensive Review.Front Pharmacol. 2021 Sep 27;12:726003. doi: 10.3389/fphar.2021.726003. eCollection 2021. Front Pharmacol. 2021. PMID: 34646135 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
